Home > Insider Trading > Filing (0000950170-24-076423)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1492422	Apellis Pharmaceuticals Inc.	APLS	Pharmaceutical Preparations (2834)	271537290

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1721108	Sinclair A. Dunlop	C/O Apellis Pharmaceuticals, Inc. 100 Fifth Avenue, 3Rd Floor Waltham MA 02451		No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2024-06-21	35,305	$39.22	138,693	No	4	S	Indirect	Indirect Owner (Epidarex)
Common Stock	Disposition	2024-06-21	1,695	$39.63	136,998	No	4	S	Indirect	Indirect Owner (Epidarex)

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	Indirect Owner (Epidarex)
No	4	S	Indirect	Indirect Owner (Epidarex)

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	133,518	Direct
Common Stock	31,855	Indirect	Indirect Owner (Masa)

Footnotes

These sales were effected pursuant to a non-Rule 10b5-1 trading plan adopted by Epidarex Capital I LP on March 2, 2024.
This transaction was executed in multiple trades at prices ranging from $38.59 - $39.58. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected in footnotes (1) and (2) of this Form 4.
This transaction was executed in multiple trades at prices ranging from $39.59 - $39.67. The price reported above reflects the weighted average sale price.
The securities are held by Epidarex Capital I, LP ("Epidarex") and the reporting person, a general partner of Epidarex, may be deemed to have voting and dispositive power over the shares held by Epidarex. The reporting person disclaims beneficial ownership over the shares held by Epidarex except to the extent of his pecuniary interest therein.
The securities are held by MASA and the reporting person, a managing partner of MASA, may be deemed to have voting and dispositive power over the shares held by MASA. The reporting person disclaims beneficial ownership over the shares held by MASA except to the extent of his pecuniary interest therein.